The Supercar Stays in the Garage: Factors Preventing Indirect Comparisons of Novel Medicines Targeting the Same Condition

No outside funding supported the writing of this letter. Ollendorf reports advisory board and consulting fees from DBV Technologies, EMD Serano, Gerson Lehman Group, and Sarepta Therapeutics, unrelated to the content of this research letter. Naci reports a grant from the Commonwealth Fund, unrelated to the content of this letter. The other authors have nothing to disclose.